Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
Main Authors: | Kiiskinen, Urpo, Matthaei, Stephan, Reaney, Matthew, Mathieu, Chantal, Östenson, Claes-Göran, Krarup, Thure, Theodorakis, Michael, Kiljański, Jacek, Salaun-Martin, Carole, Sapin, Hélène, Guerci, Bruno |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3713896/ |
Similar Items
-
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
by: Mathieu, Chantal, et al.
Published: (2013) -
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries
by: Östenson, Claes-Göran, et al.
Published: (2013) -
Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study
by: Reaney, Matthew, et al.
Published: (2013) -
Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study
by: Matthaei, Stephan, et al.
Published: (2012) -
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
by: Simó, Rafael, et al.
Published: (2015)